drug · small molecule
risperidone ER
Phase 3updated 6mo agoby Lyndra Therapeutics Inc.🔗 ChEMBL
Phase 3community read0 votes
🐶 often sniffed alongside
top 5Small molecule drug with a maximum clinical stage of Approval (across all indications), with 6 approved and 24 investigational indications.
targets
5-hydroxytryptamine receptor 2A5-hydroxytryptamine receptor 2CD(2) dopamine receptor
all catalysts(0)
nothing on the calendar yet
Trials studying risperidone ER
- phase4A Phase 4 Study to Assess the Effects of Aripiprazole Versus Other Atypical Antipsychotics in the Treatment of Schizophrenic Patients With Metabolic Syndrome
- phase3Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications
- phase4An Efficacy and Safety Study of Long-acting Risperidone in Participants With Schizophrenia or Schizoaffective Disorders Who Are Receiving Psychiatric Home Care Treatment
- —Long-term Antipsychotic Pediatric Safety Trial
- phase2Efficacy and Safety of MK-8189 in Participants With an Acute Episode of Schizophrenia (MK-8189-008)
- phase3Long-Term Study of MP-214 in Patients With Schizophrenia
- phase3Safety and Efficacy of MP-214 in Patients With Schizophrenia
- phase3A Long-Term Study of MP-214 in Patients With Chronic Phase or Elderly Schizophrenia
News(3)
- Ambrose Healthcare inks $181M deal for former Pfizer target AM-PharmaAmbrose Healthcare has bought AM-Pharma for up to 161 million euros, inking a cut-price deal for a biotech once courted by Pfizer.fiercebiotech · 1mo ago
- As BMS’ Cobenfy struggles to gain traction, MapLight knocks on the doorDespite the recent emergence of a new drug class, schizophrenia remains one of the most challenging neuropsychiatric diseases to treat—and Cobenfy's first steps into the market indicate there is st…biospace · 3mo ago
- Teva nabs experimental Tourette drug in $700M Emalex buyoutA Jefferies analyst argued the deal — Teva’s largest in a decade — “makes sense” given the synergies between Emalex and the pharmaceutical giant’s neurology business.biopharma_dive · 6mo ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that